Join the Acute Myeloid Leukemia group to help and get support from people like you.
Acute Myeloid Leukemia News
Related terms: Acute Granulocytic Leukemia, Acute Myelogenous Leukemia, ANLL, Cancer, Acute Granulocytic Leukemia, Cancer, Acute Myelogenous Leukemia, Cancer, Acute Myeloid Leukemia, Leukemia, Acute Granulocytic, Leukemia, Acute Myelogenous, Leukemia, Acute Myeloid, AML
CD7 Expression Tied to Poorer Outcomes With Newly Diagnosed Leukemia
FRIDAY, May 3, 2024 – CD7 expression is associated with poorer outcomes in patients with newly diagnosed acute myeloid leukemia (AML), according to a study published online April 11 in the British...
Improvements Seen in Post-Allo-HCT Outcomes for Seniors With Leukemia
THURSDAY, March 28, 2024 – For older patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT), posttransplant outcomes have improved over time,...
Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
WEDNESDAY, Feb. 21, 2024 – For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the...
Allogeneic HCT After Primary Induction Failure Beneficial in Leukemia
THURSDAY, Dec. 21, 2023 – For patients with acute myeloid leukemia (AML), immediate allogeneic hematopoietic stem cell transplantation (HCT) after primary induction failure (PIF) offers long-term...
Peripheral Blood Haplo-SCT Feasible for Leukemia Patients 70 Years and Older
WEDNESDAY, Dec. 20, 2023 – For patients with acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) aged 70 years and older, haploidentical stem cell transplantation (Haplo-SCT) using a...
Fewer Complications Seen With Vitamin C, D Supplementation in AML
WEDNESDAY, Sept. 6, 2023 – For patients with acute myeloid leukemia (AML), supplementation with vitamins C and D during chemotherapy may improve outcomes but may not improve overall survival (OS),...
Precursor to Blood Cancer Is 'Tricky to Diagnose,' Study Shows
WEDNESDAY, Aug. 9, 2023 – New research shows hard-to-diagnose blood disorders called myelodysplastic syndromes/neoplasms (MDS) are often misdiagnosed and a second opinion may be needed. The...
FDA Approves Vanflyta (quizartinib) for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
TOKYO & BASKING RIDGE, N.J. July 20, 2023 --(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that Vanflyta (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in...
Spleen Volume Linked to Outcome After HSCT for Leukemia Patients
WEDNESDAY, July 19, 2023 – For patients with acute myeloid leukemia (AML), higher spleen volume at the time of hematopoietic stem cell transplant (HSCT) is associated with inferior overall survival...
FDA Approves Rezlidhia (olutasidenib) for Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
Rezlidhia is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor Phase 2 registrational data supporting the approval showed a 35% CR+CRh rate in mIDH1 R/R AML...
Servier Announces FDA Approval of Tibsovo (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
Tibsovo is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based on data...
Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
DUBLIN, March 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos® (daunorubicin and c...
FDA Approves Onureg (azacitidine tablets) as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
PRINCETON, N.J.--(BUSINESS WIRE) September 1, 2020 --Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg (azacitidine 300 mg tablets,...
Agios Announces FDA Approval of Tibsovo as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) – Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the U.S. Food...
FDA Medwatch Alert: FDA Warns That Symptoms of a Serious Condition Affecting the Blood Cells Are Not Being Recognized with the Leukemia Medicine Idhifa (enasidenib)
The U.S. Food and Drug Administration (FDA) is warning that signs and symptoms of a life-threatening side effect called differentiation syndrome are not being recognized in patients receiving the...
Ask a question
To post your own question to this support group, sign in or create an account.